Results 151 to 160 of about 1,093,248 (283)

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Treatment of severe covid-19 with interleukin 6 receptor inhibition

BMJ Medicine, 2022
Stephen Burgess, Dipender Gill, Skanda Rajasundaram   +2 more
doaj   +1 more source

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

Advanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad, M. Akif Rahman, Ahmad Amiri   +2 more
wiley   +1 more source

Interleukin-6 in Natural and Pathophysiological Kidney Aging. [PDF]

Cells
Mutig K, Singh PB, Lebedeva S.
europepmc   +1 more source

Cold Atmospheric Plasma‐Activated Decellularized Extracellular Matrix Gel as a Tumor‐Infiltrating Immunoactivation Platform for Post‐Surgical Cancer Immunotherapy

Advanced Materials, EarlyView.
An injectable cold atmospheric plasma‐activated decellularized tumor extracellular matrix hydrogel is introduced as a post‐surgical immunoactivation platform. The engineered gel attracts residual tumor cells and induces immunogenic cell death, reshaping the tumor microenvironment and eliciting systemic antitumor immunity. In combination with checkpoint
Tianxu Fang, Mo Chen, Yueyang Deng, Tianqin Ning, Tianwen Luo, Guojun Chen   +5 more
wiley   +1 more source

Role of Interleukin-6 in Atherothrombosis and Myocardial Infarction. [PDF]

Curr Atheroscler Rep
Huse C, Gregersen I, Holme FA, Ueland T, Skjelland M, Aamodt AH, Dahl TB, Aukrust P, Halvorsen B.   +8 more
europepmc   +1 more source

Soft Ionic and Electronic Triboelectric Nanogenerators: Toward Attachable and Implantable Biomedical Applications

Advanced Materials, EarlyView.
This review provides an overview of triboelectric nanogenerator (TENG)–based biomedical applications by classifying studies into electronic and ionic systems across attachable and implantable platforms. It summarizes key material choices, device structures, and working mechanisms that characterize current TENG‐based research, and outlines six future ...
Kyongtae Choi, Jimin Park, Won Jun Song, Soohwan An, Seonggyu Choe, Byeong‐Rak Keum, Min Young Kim, Dae Hee Hwang, Young‐Geun Park, Sung‐Won Kim, Sangyul Baik, Gwang‐Bum Im, Younghoon Lee   +12 more
wiley   +1 more source

Interleukin-6 regulates the neutrophil response to diverse bacteria. [PDF]

Front Immunol
Owens JM, Weppner HK, Ignes-Romeu A, Burleson JW, Hind LE.   +4 more
europepmc   +1 more source

Efficacy and Safety Assessment of 5‐Fluorouracil, Irinotecan and Oxaliplatin‐Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy

Advanced Materials, EarlyView.
A novel FIRINOX‐loaded implant demonstrates controlled drug release, and potent therapeutic efficacy in pancreatic ductal adenocarcinoma mouse models with safety confirmed in a large‐animal pre‐clinical model. This innovative drug delivery platform offers a promising new treatment approach for non‐resectable, treatment‐resistant pancreatic cancer ...
Samantha J. Wade, Ashna A. Kumar, Samuel O. Nitschke, Paul Joyce, Elahe Minaei, Stephanie E. Reuter Lange, Chelsea Penney, Holly Warren, Ruby Shepherd, Jeremy N. Dinoro, Gordon G. Wallace, Anthony Dosseto, Sameera Ansar, Naila Islam, Alistair Lochhead, George Sharbeen, Phoebe A. Phillips, Morteza Aghmesheh, Wayne J. Hawthorne, Kara L. Vine‐Perrow   +19 more
wiley   +1 more source

Type I interferon limits interleukin-6 signalling in SLE through shedding interleukin-6 receptors. [PDF]

Rheumatology (Oxford)
Hempel M, Klapproth E, Krause A, Becker-Pauly C, Zeissig S, Heschel B, Weser N, Fantana J, Leuchten N, Rose-John S, El-Armouche A, Korb-Pap A, Aringer M.   +12 more
europepmc   +1 more source